- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Teva, Celltrion Launch Fourth Trastuzumab Biosimilar
Teva Pharmaceuticals USA and Celltrion Healthcare have launched the fourth trastuzumab biosimilar, Herzuma, at a 10% discount to the cost of reference product Herceptin.
Three months after its FDA approval, a fourth trastuzumab biosimilar has been launched. Teva Pharmaceuticals USA and Celltrion Healthcare announced the market availability of Herzuma (trastuzumab-pkrb), an injectable biosimilar with the same indications as the Herceptin reference product.
The biosimilar arrival on market follows launches of other biosimilars for trastuzumab by Pfizer (Trazimera), Mylan/Biocon (Ogivri), Amgen/Allergan (Kanjinti). An additional trastuzumab biosimilar approved but not yet launched is Samsung Bioepis’ Ontruzant.
Herzuma is indicated for the treatment of breast cancer in the adjuvant setting, metastatic breast cancer, and metastatic gastric cancer.
The wholesale acquisition cost (WAC) for Herzuma 150 mg is $1402.50 and HERZUMA 420 mg is $3927, which is a 10% discount to the WAC of Herceptin, Teva and Celltrion said in a release. They said actual costs for Herzuma are expected to be lower because WAC does not account for rebates and further discounts that may apply.
“We are proud to make Herzuma available to patients in the United States living with HER2-positive breast and gastric cancers, and their providers,” said Brendan O’Grady, executive vice president, North America Commercial, Teva.
Teva and Celltrion also are partners on a biosimilar for rituximab, whose reference product is Rituxan. Teva and Celltrion’s version, Truxima, was approved November 28, 2018, and was launched in November 2019. The product also was being offered at a 10% discount to the list price of reference product. Truxima was made available at $845.55 for a 100-mg vial and $4227.75 for a 500-mg vial.
Although the reference rituximab also carries indications for inflammatory diseases including rheumatoid arthritis, Celltrion sought and received approval only for adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) either as monotherapy or in combination with chemotherapy.
Related Stories
Pfizer Launches Trastuzumab Biosimilar
Pipeline Report: Oncology Biosimilars to Advance in 2020
Pfizer Touts Lower WAC of 3 Oncology Biosimilars as It Launches Rituximab Product
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
